Fluvoxamine Shows Promise in Alleviating Long COVID Fatigue
A recent randomized clinical trial suggests that the low-cost antidepressant fluvoxamine may offer relief for individuals experiencing long COVID fatigue. The study, which included 399 adults, indicated that fluvoxamine significantly reduced fatigue and improved quality of life compared to a placebo. This finding positions it as one of the first medications to demonstrate meaningful benefits for this disabling condition.
A randomized clinical trial has explored the potential of fluvoxamine, a common low-cost antidepressant, in addressing the persistent fatigue associated with long COVID.
The trial involved 399 adult participants and compared the effects of fluvoxamine against a placebo. The objective was to assess the medication's impact on long COVID symptoms, particularly fatigue.
Results from the study indicated that participants receiving fluvoxamine experienced a significant reduction in fatigue levels. Additionally, the medication was associated with an improvement in the overall quality of life for those struggling with long COVID. This outcome highlights fluvoxamine as one of the initial medications to show meaningful positive effects for this challenging health condition.
According to Science Daily, these findings could offer new hope for individuals seeking effective treatments for long COVID-related fatigue.
